Biomarkers

Purple Biotech has revealed positive new results from exploratory analyses conducted as part of a Phase I dose escalation study into CM24 plus nivolumab for advanced cancer. The study enrolled 14 patients with advanced cancers including 11 patients with pancreatic adenocarcinoma (PDAC), two patients with colorectal adenocarcinoma (CRC) and one patient with papillary thyroid cancer. […]

Ahead of this year’s SLAS2023 conference in San Diego (which takes place 25 February – 1 March) DDW’s Megan Thomas narrates articles from the DDW SLAS2023 supplement as part of the DDW Events podcast series. This is episode two, Acquiring deeper insights and acceleration with AI. At IBM Research, a group of scientists and researchers […]

Following a resubmission from manufacturer Merck, the Scottish Medicines Consortium (SMC) has now approved Tepmetko (tepotinib) for use on the NHS in Scotland.   It is recommended for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) harbouring mesenchymal-epithelial transition factor gene (MET) exon 14 (METex14) skipping alterations.   This change was made following […]

A Phase IIa study of Alto Neuroscience’s ALTO-100 has demonstrated clear evidence of efficacy and a favourable safety record in patients with major depressive disorder (MDD).   In the study, patients with a biomarker profile that ties back to a mechanistic understanding of ALTO-100 and depression exhibited a significantly greater change in Montgomery-Åsberg Depression Rating Scale […]

Several new products for the life sciences sector have been launched over the last month, from biomarker kits to video-based training platforms. DDW provides an update.  Breath Biopsy VOC Atlas – Owlstone Medical  The Breath Biopsy VOC Atlas is a catalogue of validated and quantitated volatile organic compounds (VOCs) found on breath, designed to assist […]

Extensive manipulation, mechanical force and labelling methods used to enrich cells activate transcriptional programs that mask molecular profiles truly significant to any underlying disease. The consequence is the identification of drug targets that are not relevant to the biological process under study.  Based on Nakhoda and Olszanski, 2022 (Addressing Recent Failures in Immuno-Oncology Trials to […]

Extensive manipulation, mechanical force and labelling methods used to enrich cells activate transcriptional programs that mask molecular profiles truly significant to any underlying disease. The consequence is the identification of drug targets that are not relevant to the biological process under study.  Based on Nakhoda and Olszanski, 2022 (Addressing Recent Failures in Immuno-Oncology Trials to […]

Extensive manipulation, mechanical force and labelling methods used to enrich cells activate transcriptional programs that mask molecular profiles truly significant to any underlying disease. The consequence is the identification of drug targets that are not relevant to the biological process under study.  Based on Nakhoda and Olszanski, 2022 (Addressing Recent Failures in Immuno-Oncology Trials to […]

Extensive manipulation, mechanical force and labelling methods used to enrich cells activate transcriptional programs that mask molecular profiles truly significant to any underlying disease. The consequence is the identification of drug targets that are not relevant to the biological process under study.  Based on Nakhoda and Olszanski, 2022 (Addressing Recent Failures in Immuno-Oncology Trials to […]

Extensive manipulation, mechanical force and labelling methods used to enrich cells activate transcriptional programs that mask molecular profiles truly significant to any underlying disease. The consequence is the identification of drug targets that are not relevant to the biological process under study.  Based on Nakhoda and Olszanski, 2022 (Addressing Recent Failures in Immuno-Oncology Trials to […]